Inventors and Patents From the City of Irvine
Inventors and Patents From the City of Irvine
Irvine is home to several large companies, including Mazda, who moved there in the early 1980s. Other notable companies include Edwards Lifesciences, which invented the heart valve, and Allergan, Inc., which is the world’s largest eye-care company. These large firms grew into dominant species in a new ecosystem or “cluster” that attracted venture capitalists, accelerators, and other specialist suppliers.
Allegiance has been assigned a patent for a “disposable surgical suction/irrigation trumpet valve tube cassette”
The device comprises two halves, the front half having an infusion line that engages a T-shaped intersection 250. The front half also has an aspiration line that enters the cassette through an aperture 256. The back half has a pump segment 258, which engages roller heads 214 at the arc-shaped exterior 256. The front half also has a sensor 280a that mates with a hole 94a in the back half.
The device has a main body 15 that includes connection 111 and 112 and a piston rise check valve and vent 2306. The main body may also comprise a filter unit 70 and a fluid trap 2310.
The cassette comprises two halves. One cassette has a luer 68, and the other half has a vent line. The cassette also has an interrupter bar 76.
The device can be used in surgical procedures to collect and dispose of liquid waste. The fluid may be fluid such as blood, resected tissue, or irrigation fluid. The fluid may also include particulate matter, such as smoke and gases.
The liquid collection system is shown schematically in FIGS. 16-28 and may include a valve or valves that are connected to a disposal line. Alternatively, the valves may be attached to a wall or be mobile.
A liquid collection bag 30 comprises a lid 31 and a flexible liner 35. The lid may include a holding mechanism, such as a strap or band, that maintains the liner portion of the collection bag in a collapsed state during evacuation. The lid also functions as a sealing member. A second vacuum connector 64 may serve the same function.
Analog Devices has been assigned a patent for circuits and methods for reducing minimum supply for register file cells
One aspect of this invention relates to a method of reducing the minimum supply for register file cells. The method involves a comparator with a first input and a second output. The comparator includes a first and second set of transistor devices connected in series. The second set of transistor devices is connected to the first node through a third terminal.
Another aspect of the invention is an oxidation barrier layer. The first oxidation barrier layer forms a barrier layer over the physical surfaces of the first semiconductor die and the second semiconductor die. The first layer acts as a pre-charge, while the second layer provides a return current to bring the first supply voltage back up to the target level.
The second aspect of the invention relates to the cellular communication network. According to the method, the network can identify interference parameters associated with communications over another UE. These signals can originate from the base station itself or a neighboring base station. The base station transmits these interference parameters to the UE, which receives one or more of them. The one or more parameters comprise information on whether inter-cell or intra-cell interference is likely to occur.
In addition to implementing the minimum supply reduction technique, the patents also address a range of related technologies. In the metro Dallas-Fort Worth area, the patents have been awarded by companies like Accenture and Toyota. One example is the system that automatically identifies products by detecting the direction of movement of a sensor. Another is a baby monitor system that works on multi-model image processing.
Life Technologies has been assigned a patent for violet laser excitable dyes
Life Technologies has received a patent for a new type of violet laser excitable dye, and the technology is poised to revolutionize the field of molecular biology. Existing violet laser excitable dyes suffer from a number of drawbacks, including poor absorbtivity, low quantum yields, and difficulty in solubilization in aqueous solutions. One of the most widely used violet laser excitable dyes, Cascade Yellow, is relatively dim when conjugated to carrier molecules and solid supports and tends to aggregate in aqueous solutions.
The dye compounds of the present invention exhibit high absorption at 350-500 nm and large Stokes shift, making them ideal for multiplexing experiments and use with existing violet lasers. The dye compounds are based on the Cascade Yellow fluorophore. These dye analogs were tested and showed surprising results.
The new series of SuperNova dyes are formulated for use with flow cytometry protocols. Their violet laser excitability increases their staining index and minimizes background. The new polymer dyes are highly compatible with existing flow cytometry protocols, including those for detecting dimly expressed cell populations. They can be easily incorporated into existing flow cytometry panels. If multiple polymer dyes are used in a single experiment, an additional buffer should be used to reduce background staining.
Analog Devices has been assigned a patent for a “modulator of cystic fibrosis transmembrane conductance regulator”
Cystic fibrosis is a disease with a high prevalence and poor prognosis. It is caused by a mutation in the CFTR gene that affects its quantity, stability, and channel gating. The CFTR gene is one of the most important regulators of fluid flow in the body.
CFTR mutations lead to multi-organ failure. CFTR modulators can correct this condition by improving protein trafficking and processing defects in affected cells. Two approved CFTR inhibitors, ivacaftor and lumacaftor, are already on the market. Further studies are needed to determine if these new therapies will be effective in treating the disease, but these new drugs have the potential to improve the lives of patients.
Moreover, this new device can also be used to regulate the amount of fluid flowing through the lung. Its design allows it to be incorporated in existing cystic fibrosis therapy devices. The patented product uses a single-channel, high-voltage r-f type regulator and a single-channel, high-frequency RF converter. This combination allows for dynamic response to varying loads.
The research was performed using a model of cystic fibrosis. The cells were seeded onto fibronectin-coated Snapwell inserts. After 24 h, the apical medium was removed. The transepithelial resistance was monitored using an EVOM epithelial volt-ohmmeter. When resistance was 300-400 O cm2, the HBE cells were treated with 0.1% dimethylsulfoxide. Then, they were exposed to 10 mM of test compound. VX-809 therapy was administered to these cells. The short-circuit current was then measured with a VCCMC6 multichannel current-voltage clamp.
The CFTR corrector glafenine inhibits the activation of prostaglandin E2 receptor 4. Glafenine, a glafenine analog, inhibits the depolarization of membranes induced by forskolin + genistein. In addition to inhibiting CFTR activity, glafenine also inhibits protein degradation in the cells.
The CFTR modulator therapies are used to treat patients who have either nonsense mutations in the gene or missense mutations in the CFTR gene. The modulators are expected to delay the onset of structural lung damage in patients with CF.
Inventors and Patents From the City of Memphis
Inventors And Patents From The City Ofbridgeport
Free Patent Filing Assistance In Henderson
Inventors and Patents From the City of Tecumseh
Inventors and Patents From the City of Moreno Valley